ArticleTranslational stroke research2018
Worse Outcome in Stroke Patients Treated with rt-PA Without Early Reperfusion: Associated Factors.
Article in Translational stroke research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it, 37 citations in OpenAlex.
- Association between plasma ADAMTS13 levels/activity and the risk of ischemic stroke and outcomes of recanalization therapies: a systematic review and meta-analysis.Frontiers in neurology · 2025Pooled it
- Argatroban Increased the Basal Vein Drainage and Improved Outcomes in Acute Paraventricular Ischemic Stroke Patients.Medical science monitor : international medical journal of experimental and clinical research · 2020Trial
- ADAMTS13 activity is associated with early neurological improvement in acute ischemic stroke patients treated with intravenous thrombolysis.Journal of thrombosis and thrombolysis · 2020Trial
- Machine Learning-Driven Identification of Blood-Based Biomarkers and Therapeutic Agents for Personalized Ischemic Stroke Management.Journal of cardiovascular translational research · 2025Article
- Effects of glycemic indicators on early neurological outcomes in patients with acute ischemic stroke treated with intravenous thrombolysis.World journal of diabetes · 2025Article
- Molecular and Neuroimaging Profile Associated with the Recurrence of Different Types of Strokes: Contribution from Real-World Data.Journal of clinical medicine · 2025Article
- Pharmacological preclinical comparison of tenecteplase and alteplase for the treatment of acute stroke.Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2024Article
- Precision Medicine for Blood Glutamate Grabbing in Ischemic Stroke.International journal of molecular sciences · 2024Observational
- Increased sensitivity in detection of deficits following two commonly used animal models of stroke.Behavioural brain research · 2024Article
- Peripheral Lymphocyte-to-Monocyte Ratio as a Predictive Factor for Early Neurological Deterioration in Patients with Acute Ischemic Stroke.International journal of general medicine · 2024Article
- Integrative Approaches in Acute Ischemic Stroke: From Symptom Recognition to Future Innovations.Biomedicines · 2023Review
- Fibrin-Targeted Nanoparticles for Finding, Visualizing and Characterizing Blood Clots in Acute Ischemic Stroke.Pharmaceutics · 2022Article
- Neurological Instability in Ischemic Stroke: Relation with Outcome, Latency Time, and Molecular Markers.Translational stroke research · 2022Observational
- Unraveling the potential of endothelial progenitor cells as a treatment following ischemic stroke.Frontiers in neurology · 2022Review
- Diabetes Mellitus/Poststroke Hyperglycemia: a Detrimental Factor for tPA Thrombolytic Stroke Therapy.Translational stroke research · 2021Review
- Insights into the regulatory role of Plexin D1 signalling in cardiovascular development and diseases.Journal of cellular and molecular medicine · 2021Review
- Imaging Acute Stroke: From One-Size-Fit-All to Biomarkers.Frontiers in neurology · 2021Review
- sTWEAK as Predictor of Stroke Recurrence in Ischemic Stroke Patients Treated With Reperfusion Therapies.Frontiers in neurology · 2021Article
- The presence of leukoaraiosis enhances the association between sTWEAK and hemorrhagic transformation.Annals of clinical and translational neurology · 2020Observational
- Temperature-Induced Changes in Reperfused Stroke: Inflammatory and Thrombolytic Biomarkers.Journal of clinical medicine · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 2 institutions in 2 countries.
Funding
Abstract
Based on preclinical studies suggesting that recombinant tissue plasminogen activator (rt-PA) may promote ischemic brain injuries, we investigated in patients the possible risk of worse clinical outcome after rt-PA treatment as a result of its inability to resolve cerebral ischemia. Here, we designed a cohort study using a retrospective analysis of patients who received treatment with intravenous (4.5-h window) or intraarterial rt-PA, without or with thrombectomy. Controls were consecutive patients who did not receive recanalization treatment, who met all inclusion criteria. As a marker of reperfusion, we defined the variable of early neurological improvement as the difference between the score of the National Institute of Health Stroke Scale (NIHSS) (at admission and 24 h). The main variable was worsening of the patient's functional situation in the first 3 months. To compare quantitative variables, we used Student's t test or the Mann-Whitney test. To estimate the odds ratios of each independent variable in the patient's worsening in the first 3 months, we used a logistic regression model. We included 1154 patients; 577 received rt-PA, and 577 served as controls. In the group of patients treated with rt-PA, 39.4% who did not present clinical reperfusion data developed worsening within 3 months after stroke compared with 3.5% of patients with reperfusion (P < 0.0001). These differences were not significant in the control group. In summary, administration of rt-PA intravenously or intraarterially without reperfusion within the first 24 h may be associated with a higher risk of functional deterioration in the first 3 months.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.